Coherus BioSciences Inc.

2.18+0.0700+3.32%Vol 3.77M1Y Perf -67.93%
Nov 29th, 2023 16:00 DELAYED
BID2.17 ASK2.20
Open2.15 Previous Close2.11
Pre-Market- After-Market2.20
 - -  0.02 0.88%
Target Price
17.25 
Analyst Rating
Moderate Buy 1.67
Potential %
691.28 
Finscreener Ranking
★★     45.47
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
     32.27
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
     39.26
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.84 
Earnings Rating
Strong Buy
Market Cap242.77M 
Earnings Date
6th Nov 2023
Alpha-0.01 Standard Deviation0.16
Beta0.87 

Today's Price Range

2.132.34

52W Range

1.4310.99

5 Year PE Ratio Range

-2.7019.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.92%
1 Month
-27.57%
3 Months
-58.40%
6 Months
-47.47%
1 Year
-67.93%
3 Years
-88.19%
5 Years
-80.29%
10 Years
-

TickerPriceChg.Chg.%
CHRS2.180.07003.32
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.60
0.97
34.25
-8.60
Leverage Ratio -14.80
ProfitabilityValueIndustryS&P 500US Markets
71.60
-104.50
-103.00
-
-99.13
RevenueValueIndustryS&P 500US Markets
165.69M
2.13
63.96
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.45-0.3815.56
Q02 2023-0.66-0.4925.76
Q01 2023-0.77-0.89-15.58
Q04 2022-0.87-0.7612.64
Q03 2022-0.79-1.11-40.51
Q02 2022-0.96-0.6532.29
Q01 2022-0.80-1.24-55.00
Q04 2021-0.61-0.601.64
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.32-357.14Negative
12/2023 QR-0.070.00-
12/2023 FY-2.17-10.15Negative
12/2024 FY-0.72-2 500.00Negative
Next Report Date-
Estimated EPS Next Report-0.45
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume3.77M
Shares Outstanding111.36K
Shares Float99.13M
Trades Count17.64K
Dollar Volume8.41M
Avg. Volume4.45M
Avg. Weekly Volume2.47M
Avg. Monthly Volume6.74M
Avg. Quarterly Volume4.13M

Coherus BioSciences Inc. (NASDAQ: CHRS) stock closed at 2.18 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 3.77M shares and market capitalization of 242.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 317 people. Coherus BioSciences Inc. CEO is Dennis M. Lanfear.

The one-year performance of Coherus BioSciences Inc. stock is -67.93%, while year-to-date (YTD) performance is -72.47%. CHRS stock has a five-year performance of -80.29%. Its 52-week range is between 1.4301 and 10.9907, which gives CHRS stock a 52-week price range ratio of 7.84%

Coherus BioSciences Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 73.19, a price-to-sale (PS) ratio of 4.22, a price to cashflow ratio of 20.10, a PEG ratio of 3.59, a ROA of -47.25%, a ROC of -53.53% and a ROE of -4 085.49%. The company’s profit margin is -99.13%, its EBITDA margin is -103.00%, and its revenue ttm is $165.69 Million , which makes it $2.13 revenue per share.

Of the last four earnings reports from Coherus BioSciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Coherus BioSciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Coherus BioSciences Inc. is Moderate Buy (1.67), with a target price of $17.25, which is +691.28% compared to the current price. The earnings rating for Coherus BioSciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Coherus BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Coherus BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.44, ATR14 : 0.30, CCI20 : -38.40, Chaikin Money Flow : -0.19, MACD : -0.37, Money Flow Index : 36.53, ROC : 3.94, RSI : 41.46, STOCH (14,3) : 48.57, STOCH RSI : 1.00, UO : 48.41, Williams %R : -51.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Coherus BioSciences Inc. in the last 12-months were: Lanfear Dennis (Option Excercise at a value of $425 915), Lanfear Dennis (Sold 223 100 shares of value $450 662 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
2 (22.22 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Strong Buy
1.44
Strong Buy
1.44

Coherus BioSciences Inc.

Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.

CEO: Dennis M. Lanfear

Telephone: +1 650 649-3530

Address: 333 Twin Dolphin Drive, Redwood City 94065, CA, US

Number of employees: 317

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

 

TipRanks News for CHRS

Tue, 26 Sep 2023 10:11 GMT Analysts Are Bullish on Top Healthcare Stocks: Coherus Biosciences (CHRS), Qiagen (QGEN)

- TipRanks. All rights reserved.

Mon, 07 Aug 2023 02:27 GMT Coherus Biosciences (CHRS) Gets a Buy from Truist Financial

- TipRanks. All rights reserved.

News

Stocktwits